Aptevo TherapeuticsAPVO -0.66%29 Dividend Yield % is 0.00% as of Jun. 27, 2026. GuruFocus rates APVO with a GF Score™ of 29/100. The stock has 1 warning sign investors should review. Among 151 Biotechnology companies, Aptevo Therapeutics ranks worse than 662250.99% on this metric.
As of today (2026-06-27), the Trailing Annual Dividend Yield of Aptevo Therapeutics is 0.00%.
The historical rank and industry rank for Aptevo Therapeutics's Dividend Yield % or its related term are showing as below:
APVO's Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.53 * Ranked among companies with meaningful Dividend Yield % only.
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
Aptevo Therapeutics Dividend Yield % Related Terms
Aptevo Therapeutics Dividend Yield % Historical Data
* Premium members only.
The historical data trend for Aptevo Therapeutics's Dividend Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
APVO vs FBLG, BGMS, AIM: Dividend Yield % Comparison
For the Biotechnology subindustry, Aptevo Therapeutics's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aptevo Therapeutics Dividend Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Aptevo Therapeutics's Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Aptevo Therapeutics's Dividend Yield % falls into.
Aptevo Therapeutics (APVO) has a Dividend Yield % of 0.00% as of Jun. 27, 2026. Dividend yield is the ratio of company dividends to the share price. View historical data on Aptevo Therapeutics and its competitors. According to the industry distribution chart, Aptevo Therapeutics ranks #999999 out of 151 companies in the Biotechnology industry.
Is Aptevo Therapeutics' Dividend Yield % too high?
Aptevo Therapeutics' current Dividend Yield % is 0.00%. Based on the distribution chart, Aptevo Therapeutics ranks #999999 out of 151 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Aptevo Therapeutics has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Aptevo Therapeutics' Dividend Yield % compare to FBLG and BGMS?
According to the Biotechnology industry distribution chart, Aptevo Therapeutics ranks #999999 out of 151 companies for Dividend Yield %. This places Aptevo Therapeutics in the lower half of its industry. The industry median Dividend Yield % is 1.53. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividend Yield % for a Biotechnology company?
The median Dividend Yield % among Biotechnology companies is 1.53, based on 151 companies in the industry. Companies in the top quartile (top 25%) have a Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividend Yield % mean?
A high Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Dividend yield is the ratio of company dividends to the share price. View historical data on Aptevo Therapeutics and its competitors. For the Biotechnology industry, the median Dividend Yield % is 1.53 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aptevo Therapeutics's current Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aptevo Therapeutics stock overvalued right now?
Aptevo Therapeutics (APVO) has a current Dividend Yield % of 0.00%. The current Dividend Yield % is 0.00%. Aptevo Therapeutics' overall GF Score™ is 29/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividend Yield % calculated?
Dividend Yield % is calculated from a company's financial statements. For Aptevo Therapeutics (APVO), the current Dividend Yield % is 0.00% as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, CD3xCD123, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.
29GF Score
Get the complete analysis for APVO
Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
APVO has been successfully added to your 
